Pluvia Biotech
- Biotech or pharma, therapeutic R&D
Pluvia Biotech develops an oral treatment for PKU. Our lead product PBAS499 shows strong pre-clinical Proof of Concept data in PKU models, broad applicability, a clean safety profile and upscaled manufacturing. We aim to be in Phase 1/2 within one year to demonstrate clinical PoC in PKU patients.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}